Discontinue if Grade 3 or 4 diarrhea or diarrhea requiring hospitalization; Grade 3 or 4 ILD or pneumonitis occur. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis; signs & symptoms of venous thrombosis & pulmonary embolism. Patients who develop Grade 3 or 4 neutropenia; persistent or recurrent Grade 2, 3 or 4 hepatic transaminase elevation. VTE eg, DVT, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian & axillary vein thrombosis, & inferior vena cava thrombosis. Initiate antidiarrheal therapy (eg, loperamide) & increase oral fluids at the 1st sign of loose stools. Monitor CBC, liver function tests prior to start of therapy, every 2 wk for 1st 2 mth & mthly for next 2 mth. Severe renal impairment (CrCl <30 mL/min), ESRD & patients on dialysis. Severe hepatic impairment (Child-Pugh C). Females of reproductive potential should use effective contraception during treatment & for at least 3 wk after last dose; perform pregnancy testing prior to treatment. Pregnancy. Not to breastfeed during treatment & for at least 3 wk after last dose. Ped patients.